Ramesh Swaminathan, World CFO of pharmaceutical firm Lupin, warns that Trump tariffs may deny many within the U.S. entry to vital medicines, as a major share of those medication come from India. He additionally sees robust development potential in India’s prescription drugs market as a consequence of low penetration.